Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Esophogeal
Descriptor: In vitro studies


Reference Number: 397
Miller CT, Lin L, Casper AM, Lim J, Thomas DG, Orringer MB, Chang AC, Chambers AF, Giordano TJ, Glover TW, Beer DG. Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene. 25, 409-18 (2006)
PubMed link      E-mail link

Reference Number: 405
Tuynman JB, Buskens CJ, Kemper K, ten Kate FJ, Offerhaus GJ, Richel DJ, van Lanschot JJ. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg. 242, 840-9 (2005)
PubMed link      E-mail link

Reference Number: 486
Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, Gooding WE, Christensen JG, Hughes SJ. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia. 8, 949-55 (2006)
PubMed link      E-mail link

Reference Number: 487
Anderson MR, Harrison R, Atherfold PA, Campbell MJ, Darnton SJ, Obszynska J, Jankowski JA. Met receptor signaling: a key effector in esophageal adenocarcinoma. Clin Cancer Res. 12, 5936-43 (2006)
PubMed link      E-mail link

Reference Number: 832
Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn M, Han M, Nakagawa H, Rustgi AK. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion. Proc Natl Acad Sci U S A. 107, 11026-31 (2010)
PubMed link      E-mail link